{
    "Trade/Device Name(s)": [
        "BGM039 Blood Glucose Monitoring System",
        "BGM039 Link Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Apex BioTechnology Corp.",
    "510(k) Number": "K220421",
    "Predicate Device Reference 510(k) Number(s)": [
        "K202885"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "November 4, 2022",
    "Summary Letter Received Date": "July 20, 2022",
    "Submission Date": "February 8, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BGM039 Blood Glucose Meter",
        "BGM039 Link Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Analyzer",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for BGM039 Blood Glucose Monitoring System and BGM039 Link Blood Glucose Monitoring System for quantitative measurement of glucose in capillary whole blood",
    "Indications for Use Summary": "Intended for self-testing to quantitatively measure glucose in fresh capillary whole blood from fingertips, forearm, or palm by people with diabetes at home as an aid in monitoring effectiveness of diabetes control; not indicated for diagnosis, screening, or neonatal use",
    "fda_folder": "Clinical Chemistry"
}